申请人:Kakenyaku Kako Co., Ltd.
公开号:US04056626A1
公开(公告)日:1977-11-01
A pharmaceutical composition containing as the essential active ingredient a benzofuran derivative of the formula: ##STR1## wherein A is --COR', ##STR2## or ethyl group; B is hydrogen atom when A is --COR' ##STR3## or --COR" substituted at the 3 or 4 position of the benzofuran nucleus when A is ethyl; R is an alkyl group having 1 to 5 carbon atoms; R' is an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 3 carbon atoms or phenyl group; R" is an alkyl group having 1 to 4 carbon atoms, phenyl or phenylalkyl group wherein the alkyl moiety has 1 to 2 carbon atoms; and the substituted propoxy group is at the 3, 4, 5, 6 or 7 position of the benzofuran nucleus; or a pharmaceutically acceptable acid addition salt thereof in admixture with a pharmaceutically acceptable carrier. The pharmaceutical composition possesses a superior .beta.-adrenergic blocking activity and local anesthetic activity, and is useful for the prevention and treatment of heart diseases, hypertension and hyperthyroidism.
一种含有苯并呋喃衍生物作为主要活性成分的药物组合物,其化学式为:##STR1## 其中A为--COR',##STR2## 或乙基基团;当A为--COR'时,B为氢原子,##STR3## 或在苯并呋喃核的3或4位处取代的--COR",当A为乙基时;R为具有1至5个碳原子的烷基基团;R'为具有1至4个碳原子的烷基基团,具有1至3个碳原子的烷氧基或苯基;R"为具有1至4个碳原子的烷基基团,苯基或苯基烷基,其中烷基部分具有1至2个碳原子;取代的丙氧基基团位于苯并呋喃核的3、4、5、6或7位;或其在与药学上可接受的载体混合物中的药学上可接受的酸盐。该药物组合物具有卓越的β-肾上腺素受体阻滞活性和局部麻醉活性,适用于预防和治疗心脏疾病、高血压和甲状腺功能亢进症。